Negalstobart clinical trials
Also written IBI110.
How each study uses negalstobart is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the negalstobart studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- IBI110
- 5
Studies by the year they started
7 studies that test it; most in 2021 (3)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2021 | 3 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 2
Innovent Biologics (Suzhou) Co. Ltd. (5) · The First Affiliated Hospital of Zhengzhou University (1) · Fudan University (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test negalstobart.
- Dec 2026Induction IBI110 and Sintilimab with Chemotherapy in LA HNSCCPhase 1/2 · Fudan University
Studies
Open first, then newest update. How each study uses negalstobart is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Induction IBI110 and Sintilimab with Chemotherapy in LA HNSCCRecruitingPhase 1/2Fudan UniversityNCT06494943Written as IBI110
- IBI110 Combined With Sintilimab in Second-line Advanced or Metastatic Esophageal Squamous Cell Carcinoma(ESCC)Not yet recruitingPhase 2The First Affiliated Hospital of Zhengzhou UniversityNCT06078657Written as IBI110+Sintilimab
- Efficacy and Safety of IBI110 in Combination With Sintilimab Versus Sintilimab Alone in Neoadjuvant and Adjuvant Therapy of Radically Resectable Non-small Cell Lung CancerTerminatedPhase 1Innovent Biologics (Suzhou) Co. Ltd.NCT05088967Written as IBI110
- A Study of IBI110 in Combination With Sintilimab and Chemotherapy in Patients With Untreated Extensive-Stage Small Cell Lung CancerCompletedPhase 1Innovent Biologics (Suzhou) Co. Ltd.NCT05026593Written as IBI110
- A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous MelanomaWithdrawnPhase 1/2Innovent Biologics (Suzhou) Co. Ltd.NCT05572463Written as Sintilimab + IBI110
- A Study Evaluating the Safety, Tolerability, and Initial Efficacy of IBI110 in Subjects With Advanced Malignant TumorsStatus unknownPhase 1Innovent Biologics (Suzhou) Co. Ltd.NCT04085185Written as IBI110
- Efficacy and Safety of IBI110 Single Agent and in Combination With Sintilimab in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma (r/r DLBCL)Status unknownPhase 1Innovent Biologics (Suzhou) Co. Ltd.NCT05039658Written as IBI110 plus sintilimab
Codes
What other systems call negalstobart · ClinicalTrials.gg INT018687
- UNII (FDA) ZH12W2AA34NEGALSTOBARTOne source FDA
- NCI Thesaurus C168603NegalstobartOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | ZH12W2AA34 | NEGALSTOBART | One source FDA |
| NCI Thesaurus | C168603 | Negalstobart | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.